Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 518-527

  Algra, Annemijn M ^a   Rothwell, Peter M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; COLORECTAL CANCER; DISTANT METASTASIS; DRUG USE; ESOPHAGUS CANCER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; INCIDENCE; NEOPLASM METASTASIS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84860467522     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70112-2     Document Type: Article

References (45)

1. Jemal A, Center MM, DeSantis C, Ward EM Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
2. Oeppen J, Vaupel JW Demography. Broken limits to life expectancy. Science 2002, 296:1029-1031.
3. Gasic GJ, Gasic TB, Stewart CC Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61:46-52.
4. Gasic GJ, Gasic TB, Murphy S Anti-metastatic effect of aspirin. Lancet 1972, 300:932-933.
5. Wang D, Dubois RN Prostaglandins and cancer. Gut 2006, 55:115-122.
6. Doherty GA, Murray FE Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age?. Expert Opin Ther Targets 2009, 13:209-218.
7. Hung WC Anti-metastatic action of non-steroidal anti-inflammatory drugs. Kaohsiung J Med Sci 2008, 24:392-397.
8. Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA 1998, 95:11301-11306.
9. McIlhatton MA, Tyler J, Burkholder S, et al. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res 2007, 67:10966-10975.
10. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G Aspirin, salicylates, and cancer. Lancet 2009, 373:1301-1309.
11. Bosetti C, Gallus S, La Vecchia C Aspirin and cancer risk: a summary review to 2007. Recent Results Cancer Res 2009, 181:231-251.
12. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010, 376:1741-1750.
13. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
14. Flossmann E, Rothwell PM Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007, 369:1603-1613. on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial.
15. Rothwell PM, Price JF, Fowkes FGR, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in randomised controlled trials. Lancet 2012, published online March 21. 10.1016/S0140-6736(11)61720-0.
16. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, published online March 21. 10.1016/S0140-6736(12)60209-8.
17. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10:501-507.
18. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007, 146:361-364. U.S. Preventive Services Task Force.
19. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, 3. CD004143.
20. Lawlor DA, Davey Smith G, Bruckdorfer KR, Kundu D, Ebrahim S Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?. Lancet 2004, 363:1724-1727.
21. Flossmann E, Rothwell PM Commentary: aspirin and colorectal cancer an epidemiological success story. Int J Epidemiol 2007, 36:962-965.
22. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998, 351:233-241. The Medical Research Council's General Practice Research Framework.
23. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988, 296:313-316.
24. Farrell B, Godwin J, Richards S, Warlow C The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
25. Cole BF, Logan RF, Halabi S, et al. Aspirin for chemoprevention of colorectal adenomas: meta-analysis of the randomised trials. J Natl Cancer Inst 2009, 101:256-266.
26. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005, 294:914-923.
27. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008, 134:21-28.
28. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007, 99:608-615.
29. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007, 133:393-402.
30. Thun MJ, Namboodiri MM, Heath CW Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596.
31. Suleiman UL, Harrison M, Britton A, McPherson K, Bates T H2-receptor antagonists may increase the risk of cardio-oesophageal adenocarcinoma: a case-control study. Eur J Cancer Prev 2000, 9:185-191.
32. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004, 24:3177-3184.
33. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000, 83:112-120.
34. Menezes RJ, Swede H, Niles R, Moysich KB Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006, 17:251-256.
35. Leitzmann MF, Stampfer MJ, Ma J, et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:1108-1111.
36. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol 2005, 162:548-558.
37. Rosenberg L, Louik C, Shapiro S Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998, 82:2326-2333.
38. Blair CK, Sweeney C, Anderson KE, Folsom AR NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 2007, 101:191-197.
39. Kwan ML, Habel LA, Slattery ML, Caan B NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007, 18:613-620.
40. Chan AT, Ogino S, Fuchs CS Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
41. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378:2081-2087. on behalf of the CAPP2 Investigators.
42. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2012, 5:164-178.
43. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294:47-55.
44. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135. Steering Committee of the Physicians' Health Study Research Group.
45. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012, 172:209-216.